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In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus
Response Criteria Working Group recommended several measures to document serial evaluations of chronic
GVHD organ involvement. Provisional deﬁnitions of complete response, partial response, and progression
were proposed for each organ and for overall outcome. Based on publications over the last 9 years, the 2014
Working Group has updated its recommendations for measures and interpretation of organ and overall re-
sponses. Major changes include elimination of several clinical parameters from the determination of
response, updates to or addition of new organ scales to assess response, and the recognition that progression
excludes minimal, clinically insigniﬁcant worsening that does not usually warrant a change in therapy. The
response deﬁnitions have been revised to reﬂect these changes and are expected to enhance reliability and
practical utility of these measures in clinical trials. Clariﬁcation is provided about response assessment after
the addition of topical or organ-targeted treatment. Ancillary measures are strongly encouraged in clinical
trials. Areas suggested for additional research include criteria to identify irreversible organ damage and
validation of the modiﬁed response criteria, including in the pediatric population.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.edgments on page 997.
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Overall survival or survival to permanent resolution of
chronic graft-versus-host disease (GVHD) and discontinua-
tion of systemic immunosuppression represent long-term
clinical outcomes that are accepted as measures of mean-
ingful beneﬁt in chronic GVHD clinical trials [1-3], but theseMarrow Transplantation.
S.J. Lee et al. / Biol Blood Marrow Transplant 21 (2015) 984e999 985long-term outcomes are not suitable for early-phase studies.
Qualitative assessments of chronic GVHD manifestations can
guide clinical decisions but are not adequate for measuring
outcomes in clinical trials. To accelerate development and
approval of novel therapeutic agents in chronic GVHD,
quantitative research tools are needed to measure short-
term responses to treatment and to predict long-term clin-
ical beneﬁt.
The 2005 National Institutes of Health (NIH) recommen-
dations proposed a broad set of assessment measures that
were thought to be feasible in most academic settings and
were based on group consensus with input from sub-
specialists [4]. For this 2014 update, the reconvenedWorking
Group reviewed the literature and then used a consensus
process to reconsider each prior recommendation while
adding new recommendations. Table 1 summarizes the 2014
changes to the original 2005 recommendations. Measures
are designated as “recommended” if available data support
their use for response measurement (Table 2). Measures are
designated as “strongly encouraged” if they were previously
recommended but the interpretation of data or utility of
measures remain controversial, “exploratory” if the Working
Group believes that substantial additional research is war-
ranted before adoption, and “no longer recommended for
general chronic GVHD trials” if the measure was previouslyTable 1
2014 Changes to the 2005 Recommendations
Organ Measures 2005 Recommendation
Skin Skin response is measured using the body surface are
erythematous rash, moveable sclerosis and nonmove
sclerosis
Size of skin ulcers is documented
Eye Eye response is measured by change in Schirmer’s tes
Mouth Mouth response is measured by change in the Modiﬁ
Oral Mucosa Score. Scores range from 0-15
Oral chronic GVHD is described as hyperkeratosis chan
Patients’ symptoms of mouth dryness and mouth pai
captured on 0-10 scales
GI Change from a 0 to 1 in the NIH GI and esophagus re
measures are considered progression
Liver Liver response is measured by change in ALT, bilirubi
alkaline phosphatase
Lung Lung response is measured by change in %FEV1 and D
after calculation of the Lung Function Score
Joints and fascia Joints and fascia are not included in response assessm
Hematology Platelet count and absolute eosinophil count are colle
to measure hematologic response
Other All abnormalities are documented and attributed to c
GVHD
Ancillary Measures
Quality of life Pediatric surveys CHRI and ASK are recommended
SF36, FACT-BMT, and HAP are recommended
Functional status Two-minute walk distance is recommended
Grip strength is recommended
Karnofsky or Lansky performance status is recommen
Response Assignments
Response category Mixed response category is not recognized
Other No comment on whether responses can be assessed i
setting of additional organ-directed treatments
No comment on whether responses can be assessed i
setting of additional systemic immunosuppressive tre
ALT indicates alanine transaminase; P-ROM, photographic range of motion; CHRI,recommended, but data have demonstrated no utility or
have not been generated since 2005 (Table 3).PURPOSE OF THIS DOCUMENT
This document summarizes proposed measures and
criteria for use in clinical trials involving patients with
chronic GVHD where the goal is to demonstrate improved
patient outcomes or to obtain regulatory approval. The
measures and criteria do not necessarily apply to routine
patient care or to trials with limited resources or trials that
target speciﬁc organs. The following general principles were
applied in selecting the recommended measures:
1. The measures should be easy for all care providers to
collect and should be attainable in the outpatient
setting.
2. The criteria should be adaptable for use in adults and
children.
3. The measures should focus on the most important and
common manifestations of chronic GVHD and should
not attempt to characterize all possible clinical
manifestations.
4. Quantitative measures should be favored over
qualitative measures.2014 Recommendation
a of
able
Skin response is measured using the updated NIH Skin Score
Detailed collection of type of BSA involvement no longer
collected except for nonmoveable sclerosis
Skin and/or joint tightening is an exploratory measure
Presence or absence, not size, of skin ulcer is documented
t Eye response is measured by change in NIH Eye Score
ed Remove mucoceles from the Modiﬁed Oral Mucosa Score.
Scores range from 0-12
ges The term hyperkeratosis is replaced by lichen-like changes
n are No longer recommended. Mouth sensitivity is still captured
on a 0-10 scale.
sponse Change from a 0 to 1 in these measures is no longer
considered progression
n, and Simpliﬁcation of the deﬁnitions of improvement and
progression
LCO Lung response is measured by change in %FEV1
ent The NIH Joint and Fascia Score and the P-ROM are used to
assess joint response
cted Platelet count and absolute eosinophil count are collected
only at baseline to provide prognostic information
hronic All abnormalities are documented but the organ is not
evaluable if there is another well documented nonchronic
GVHD cause
No longer recommended
SF36 or FACT-BMT plus HAP are strongly encouraged
Two-minute walk distance provides prognostic information,
consider assessing only at baseline
No longer recommended
ded Karnofsky or Lansky performance status is strongly
encouraged only at baseline
Mixed response category is recognized and considered
progression
n the If topical or organ-directed treatments are added, any CR or
PR in those organs should be reported as occurring in the
setting of additional local therapy.
n the
atments
Addition of systemic immunosuppressive treatment is
considered treatment failure, unless otherwise speciﬁed in
the protocol
Child Health Ratings Inventories; ASK, Activities Scale for Kids.
Table 2
2014 Recommended Chronic GVHD-Speciﬁc Core Measures for Assessing Responses in Chronic GVHD Trials
Measure Clinician Assessed Patient Reported
Assessments NIH Skin Score (0-3) N/A
NIH Eye Score* (0-3)
Modiﬁed OMRS (0-12)
Total bilirubin (mg/dL), ALT (U/L)
Alkaline phosphatase (U/L)
FEV-1 (liters, % predicted)
NIH Joint Score (0-3)
P-ROM (4-25)
Symptoms NIH Lung Symptom Score (0-3) Lee Symptom Scale [7] (0-100)
Upper GI Response Score (0-3) Skin itching (0-10)
Lower GI Response Score (0-3) Mouth sensitivity (0-10)
Esophagus Response Score (0-3) Chief eye complaint (0-10)
Global rating scales None-mild-moderate-severe [7] (0-3) None-mild-moderate-severe [7] (0-3)
0-10 severity scale [8] (0-10) 0-10 severity scale [8] (0-10)
7 point change scale [9] (3 to þ3) 7 point change scale [9] (3 to þ3)
OMRS indicates Oral Mucosa Rating Scale.
* Components include both signs and symptoms.
S.J. Lee et al. / Biol Blood Marrow Transplant 21 (2015) 984e9999865. Measurements of symptoms, global ratings, function,
and quality of life should bemade separately from each
other, and scales with established psychometric char-
acteristics and desirable measurement properties
should be used whenever possible [5,6].
TheWorking Group had 3 additional goals: (1) to propose
provisional deﬁnitions of complete response (CR), partial
response (PR), and disease progression (DP) for each organ
and for overall response; (2) to suggest appropriate strate-
gies for using response measures in therapeutic clinical
trials; and (3) to outline future research directions.
SUMMARY OF RECOMMENDATIONS
1. “Chronic GVHD-speciﬁc” core measures are (a)
clinician-assessed and patient-reported signs andTable 3
Strongly Encouraged, Exploratory, and No Longer Recommended Response Measures f
Organ* Strongly Encouraged Exploratory
Skin Clinician and
skin and/or jo
Eyes
Mouth
Upper GI Weight
Lower GI Weight
Liver
Lungs Corrected DLCO, FVC, TLC, RV
Hematologic
Genitals Female and m
question: “W
on a 0-10 sca
Ancillary measures SF-36 (0-100) or FACT-BMT (0-148) in adults
HAP (if the SF-36 is not used) (0-94)
Patient overall severity score 0-10
PedsQL
Clinician and
(0-10) and ch
organ-speciﬁc
TLC indicates total lung capacity; RV, residual volume; PedsQL, pediatric quality of life
* No measures for esophagus or joints and fascia.symptoms, (b) the Lee Chronic GVHD Symptom Scale,
and (c) the clinician-assessed or patient-reported
global rating scales (Table 2) [7-9]. Easily recorded
continuous data should not be reduced to prespeciﬁed
categories.
2. “Chronic GVHD non-speciﬁc” ancillary measures for
adults include either the Medical Outcomes Study
Short Form 36-item questionnaire version 2 (SF-36)
[10,11] or the Functional Assessment of Cancer
TherapyeBone Marrow Transplantation subscale
(FACT-BMT) [12] plus the Human Activity Proﬁle (HAP)
questionnaire [13] (Table 3). These measures are
strongly encouraged but remain optional and should
not be used as primary endpoints in chronic GVHD
trials.
3. Age-appropriate modiﬁcations of existing measures
should be used in children with chronic GVHD.or General Chronic GVHD Trials
No Longer Recommended for
General Chronic GVHD Studies
patient reported
int tightening
BSA of erythematous changes and
moveable sclerosis
Pigmentary changes
Schirmer’s test
Mucoceles, patient-reported mouth
pain and dryness on a 0-10 scale
Aspartate aminotransferase
Platelet count, absolute eosinophil
count
ale self-reported
orse genital discomfort”
le
patient-reported severity
ange (-3 to þ3) for
chronic GVHD manifestations
Grip strength
CHRI for Kids
.
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Figure 1. (continued).
S.J. Lee et al. / Biol Blood Marrow Transplant 21 (2015) 984e9999884. Documenting response involves a comparison of
chronic GVHD activity at 2 time points. Deﬁnitions of
response are offered for each organ and for overalloutcomes, although each protocol should deﬁne pre-
cisely how response will be determined. Simple forms
that may be used for clinician and patient assessments
Figure 1. (continued).
S.J. Lee et al. / Biol Blood Marrow Transplant 21 (2015) 984e999 989are provided in Figures 1 and 2. Currently, objective
and subjective data are kept separately. The ﬁeld
would beneﬁt from methods that integrate physical
exam and laboratory ﬁndings with clinician- and
patient-reported information to determine accurately
whether chronic GVHD is improving or worsening.
5. Measurements should be made at regular intervals, for
example every 3 months, and whenever a new sys-
temic immunosuppressive treatment is started or the
patient stops study treatment. Efforts to document the
durability of response are strongly encouraged.
6. Collaboration with subspecialists is encouraged to
develop and validate more detailed organ- or site-
speciﬁc measures that could improve sensitivity to
change or serve as primary endpoints in organ-speciﬁc
therapy trials. For example:
a) Skin: skin-speciﬁc scoring systems [14], durometer
[14-16], histopathology [15], or imaging (ultra-
sound, magnetic resonance imaging) [17,18]
b) Eyes: corneal staining grading [19,20], conjunctival
grading [21], Ocular Surface Disease Index [22]
c) Oral: Oral Health Impact Proﬁle [14,23], saliva
analysis [24], Oral Mucosa Rating Scale [25]
d) Vulvar-vaginal: organ-speciﬁc grading [26,27]e) Function: range of motion measured by goniom-
eter, fatigue severity scale [28-30]
7. Measures that predict outcomes but are not sensitive
to change or do not directly measure chronic GVHD
manifestations should be collected at baseline but not
used in the response assessment, for example:
performance status, platelet count, eosinophils, and
the 2-minute walk test.PROPOSED MEASURES OF CHRONIC GVHD RESPONSE
ASSESSMENTS
The Working Group identiﬁed 2 broad categories of tools
for use in the assessment of response. These include (1) the
“chronic GVHD-speciﬁc” core measures that directly mea-
sure organ-speciﬁc manifestations of chronic GVHD, and (2)
the “nonspeciﬁc” ancillary measures that could reﬂect the
overall impact of chronic GVHD, treatment, comorbidity, or
other illness on function or quality of life.
Chronic GVHD-Speciﬁc Core Measures
The core clinician-assessed and patient-reported chronic
GVHD-speciﬁc measures are described in the following sec-
tions: organ-speciﬁc assessments, chronic GVHD symptoms,
Figure 2. Chronic GVHD Activity Assessment-Patient Self Report.
S.J. Lee et al. / Biol Blood Marrow Transplant 21 (2015) 984e999990and clinician- and patient-reported global ratings (Table 2;
Figures 1 and 2). Speciﬁc pediatric considerations are high-
lighted where appropriate. For the assessment of symptoms
in younger children, depending on the child’s development,
assistance can be provided by the health care provider or the
parent. The Working Group also recommends formal, inter-
active training for all assessors to minimize intra- and
interobserver variability [31-33]. Whenever possible, the
same clinician should score a patient serially to reduce
measurement error due to interobserver variability.
Organ-speciﬁc assessments
The discussion below is applicable to signs and symptoms
potentially attributable to chronic GVHD. Other documented
causes of the abnormality, such as infection, injury, or other
non-GVHD cause, should be indicated on the case report
forms, and if explained entirely by non-GVHD documentedcause, the respective organ may not be evaluable for
response assessment. The measures below reﬂect the mini-
mum data documentation in chronic GVHD trials. Some
studies will require more detailed organ assessments.
Skin and skin appendages. Skin is the most frequently
affected organ in chronic GVHD, and manifestations are
highly variable. In the 2005 Response Criteria, proposed
measures included the percentage of body surface area (BSA)
by the type of involvement (erythematous rash, movable
sclerosis, nonmoveable sclerosis). BSA measurement on a
continuous scale suffered from poor inter-rater reliability,
particularly for moveable sclerosis [32]. Thus, the 2014
revision recommends the simpler NIH Skin Score instead,
because it correlates with chronic GVHD severity, symptoms,
and survival [34]. The NIH Skin Score is a 0 to 3 score that
summarizes BSA involvement into 4 categories: no skin
S.J. Lee et al. / Biol Blood Marrow Transplant 21 (2015) 984e999 991involvement, 18% without sclerosis, 19% to 50% or any
moveable sclerosis, and >50% or any nonmoveable sclerosis,
impaired mobility, or ulcers. The “Rule of 9’s” as an estimate
of BSA involvement is intended for use in adults and is less
accurate in children, particularly young children. For the sake
of simplicity, we recommend using the “Rule of 9’s” for all
children, except for those younger than 1 year of age. A BSA
grid for children less than 1 year of age can be found at http://
www.asbmt.org/?page¼MeasureCGVHD. BSA assessment
should include superﬁcial skin eruptions, moveable sclerosis,
and nonmovable sclerosis. Superﬁcial skin eruptions of
cutaneous chronic GVHD include maculopapular, erythem-
atous, lichen planuselike, papulosquamous, ichthyotic, and
keratosis pilariselike rashes. Superﬁcial sclerosis (moveable)
includes both lichen sclerosis-like and morphea-like lesions.
Deep sclerosis (nonmoveable) includes diffuse, ﬁxed (hide-
bound) sclerosis, ﬁbrosis of subcutaneous fat septae
(“rippling”), and fasciitis (“groove sign”). The presence of
ulcers should be noted but documentation of the size is no
longer required.
Sclerotic changes are common in skin GVHD, difﬁcult to
measure reliably, and respond slowly to therapy. Because
quantitative methods to measure the depth of sclerotic
involvement are not available in a general oncology practice,
these changes have been described in more qualitative terms
related to thickening, pliability, color, adherence to under-
lying tissues, or changes in joint mobility. No validated scale
exists for assessing sclerotic skin changes of chronic GVHD.
Measures such as the Rodnan scale for assessment of sys-
temic sclerosis might be helpful for clinical evaluation, but
this scale is not suitable for use in clinical trials because it
does not address the full spectrum of sclerotic skin mani-
festations in chronic GVHD. There is an urgent need for the
development of more quantiﬁable and reproducible mea-
surements or imagingmethods that could be used in patients
with sclerotic skin manifestations of chronic GVHD [14-18].
Pending development of these measures, theWorking Group
recommends recording the percentage of BSA involved with
deep sclerosis/fasciitis and using an exploratory 0 to 10
semiquantitative scale for capturing clinician-perceived
severity of sclerosis using the descriptor skin and/or joint
tightening.
Pigmentary changes do not indicate chronic GVHD
disease activity per se. Moreover, changes in pigmentation
occur gradually and are perceptible only across long time
intervals. Thus, these changes are not scored for the purposes
of response assessment.
Patient-reported measures of skin disease are also useful
for measuring response. The skin subscale of the Lee Symp-
tom Scale correlates with severity of skin disease, and
changes in patient-reported skin symptoms correlate with
survival [34]. Patients should report their most severe itching
during the past week, rated according to a 0 to 10 scale, as
itching is the most frequent cutaneous symptom of chronic
GVHD. These are considered recommended measures. A
semiquantitative exploratory measure, “Your skin and/or
joint tightening at its worst,” on a 0 to 10 scale has been
added to capture severity of skin sclerosis. Informal cognitive
testing suggested that including both “skin” and “joint”
tightening in the question was not confusing for patients.
Musculoskeletal connective tissue. Assessment of joint range
of motion is a very useful objective measure of chronic GVHD
tissue response in patients with sclerotic changes involving
large joints. The NIH Joint Score and the photographic rangeof motion scales correlate with change in joint involvement,
and are recommended measures [35].
Eyes. Dry eyes represent either lacrimal gland dysfunction or
destruction that may be permanent. Although the Schirmer’s
test [36] was recommended in the 2005 criteria, subsequent
studies have not supported the validity of this test in ocular
chronic GVHD monitoring, and it is no longer recommended
as a response measure for general chronic GVHD clinical
trials [37]. The NIH Eye Score is a recommended measure, as
it detects improvement or worsening in ocular chronic GVHD
[37]. Scoring from 0 to 3 is based on symptoms, need for eye
drops, and use of therapeutic procedures or devices.
Patients should report a “chief eye complaint” rated ac-
cording to a 0 to 10 scale for peak severity during the past
week. The complaint can change fromvisit to visit, but only 1
“chief eye complaint” is graded. This method is simple to use
but may impose undesirable limitations in patients with
multiple complaints. The eye subscale of the Lee Symptom
Scale and the Ocular Surface Disease Index are also sensitive
to change [37], but the Lee eye subscale is more convenient
as it is shorter and is already included in the composite
symptom battery.
Mouth. Previously, oral chronic GVHD was assessed using an
NIH modiﬁcation of the Schubert Oral Mucosa Rating Scale
[25] that scores oral surfaces from 0 to 15, with higher scores
indicating more severe involvement. The 4 2005 NIH
Consensus chronic GVHD manifestations assessed in this
scale included (1) mucosal erythema (color intensity and
percent of oral surface area), (2) lichen-like hyperkeratosis
(percent of oral surface area), (3) ulcerations (percent of oral
surface area), and (4) mucoceles (total number). Subsequent
studies have suggested that mucoceles are not reliably
assessed [32,33,38] and their enumeration does not correlate
with important clinical outcomes [38,39]. Thus, the Working
Group recommends removing mucoceles from the NIH-
modiﬁed Oral Mucosa Rating Scale, resulting in a further
modiﬁed 0 to 12 scale. The term hyperkeratosis has been
removed and clariﬁed as “lichen-like changes” instead.
Patients should report their mouth sensitivity (irritation
resulting from normally tolerated spices, foods, liquids, or
ﬂavors), rated according to a 0 to 10 scale for peak severity
during the past week. Children may have an easier time with
a 0 to 3 scale, but this format has not been validated andmay
be less sensitive to change. Evaluation of mouth dryness and
mouth pain on 0 to 10 scales is no longer recommended for
general chronic GVHD trials [40]. Mouth symptoms are also
captured in the Lee Symptom Scale, as part of a recom-
mended battery.
Hematopoietic. Parameters to be documented at trial
enrollment include platelet count [41] and absolute eosino-
phil count [42,43] as they may have prognostic signiﬁcance.
These measures are not part of the response assessment, and
their ongoing documentation is no longer recommended.
Gastrointestinal tract. Gastrointestinal (GI) symptoms are
difﬁcult to measure quantitatively. GI symptoms during the
preceding week are graded through interview by the
examining clinician according to 0 to 3 severity scales for the
upper and lower GI tract and esophagus. Patients with
chronic GVHD often have weight loss that is not explained by
GI symptoms [44]. Although the exact relationship between
weight loss and chronic GVHD activity is not clear, recording
S.J. Lee et al. / Biol Blood Marrow Transplant 21 (2015) 984e999992patient weight at each scheduled evaluation is strongly
encouraged, given the simplicity of this measure and its
potential importance for monitoring the success of therapy.
Liver. Liver injury should be assessed according to the most
recent laboratory results for total serum bilirubin (mg/dL),
alkaline phosphatase (U/L), and alanine aminotransferase
(U/L). Laboratory upper limits of normal should also be
recorded. Aspartate aminotransferase is not recorded as it is
not speciﬁc for liver inﬂammation.
Lung. The 2005 response criteria recommended the lung
function score, based on percent predicted forced expiratory
volume in the ﬁrst second (%FEV1) and single breath diffu-
sion lung capacity for carbon monoxide (DLCO) adjusted for
hemoglobin, because it is predictive of respiratory failure and
mortality after allogeneic hematopoietic stem cell trans-
plantation [45,46]. Experience in patients with steroid-
refractory GVHD has suggested that the lung function score
is sensitive to change and is useful as a response measure
[47]. On the other hand, DLCO is not directly affected by
bronchiolitis obliterans syndrome (BOS), and pulmonary
function tests (PFTs) did not perform as well as the NIH Lung
Symptom Score in predicting nonrelapse mortality and sur-
vival in an observational study, although conclusions were
limited by 50% missing PFT data [48]. PFTs cannot be per-
formed in children younger than 5 years of age, and DLCO
usually cannot be measured in children younger than 10
years. FEV1 may not be reliable in children [49]. Another
therapeutic study that included mostly BOS patients showed
that a decrease in %FEV1 or forced vital capacity of greater
than 10% was highly correlated with an increased risk of
death within 5 years [50].
The Working Group recommends recording the %FEV1,
FEV1 (liters [L]), and forced vital capacity, and strongly en-
courages parallel documentation of DLCO corrected for he-
moglobin, total lung capacity, and residual volume to allow
further validation studies, including exploration of restrictive
lung disease as a manifestation of chronic GVHD [51-53]. If
available, the %FEV1 value should be prioritized for response
assessment. However, if PFTs are not available, the NIH 0 to 3
Lung Symptom Score may be used for response assessment.
Of note, airway hyper-responsiveness in, and variable coop-
eration by, pediatric patients may require repeated PFTs in
cases where abnormal values are observed. %FEV1 may
decline because of respiratory infections or progressive
restrictive physiology due to extrinsic thoracic compression
from sclerosis or respiratory muscle weakness, and these
causes should be considered if PFTs worsen. Exploration of
the %FEV1 slope as an outcome measure to account for the
change in disease trajectory is encouraged [54,55]. Chronic
GVHD of the lung is not a bronchodilator-responsive process,
so bronchodilators are not required to assess response for
general chronic GVHD trials. Patients with reactive airways,
disease such as asthma, who have a documented broncho-
dilator response should continue to receive bronchodilators
during PFTs.
Genitals. Women should be asked speciﬁc questions relating
to vulvar and vaginal symptoms, such as burning, pain,
discomfort, or dyspareunia. Patients who report problems
should be referred to a gynecologist experienced in the care
of patients with chronic GVHD. Because such symptoms
could be under-reported or caused by conditions other than
chronic GVHD [56] and because proper evaluation requires aspecialist exam, measures of genital response are considered
exploratory. Both female and male genital symptoms may be
captured by the exploratory item rating “worst genital
discomfort” on a scale from 0 to 10 in adolescent and adult
patients, whereas this item will not work in pediatric pa-
tients. Academic gynecologists interested in chronic GVHD
are developing precise vulvo-vaginal assessment scales.
These scales will be useful in selected trials where vulvar and
vaginal changes are the primary endpoints of interest
[26,27].
Other organ systems may be affected by chronic GVHD
but are either uncommon or difﬁcult to quantify by non-
specialists. The Working Group encourages investigators to
develop and validate response assessment tools that could
detect meaningful clinical beneﬁt in trials focused on speciﬁc
organs or manifestations.
Chronic GVHD symptoms
Lee and colleagues developed a symptom scale designed
for individuals with chronic GVHD [7]. The questionnaire
asks patients to indicate the degree of “bother” that they
experienced during the past 4 weeks due to symptoms in 7
domains potentially affected by chronic GVHD (skin, eyes
and mouth, breathing, eating and digestion, muscles and
joints, energy, emotional distress). Published evidence sup-
ports its validity, reliability, and sensitivity to chronic GVHD
severity [34,37,48,57,58]. The symptom scale can be
completed in approximately 5 minutes. The reporting time
frame may be decreased to 1 week to speciﬁcally capture
more recent symptoms.
The Lee Symptom Scale has been tested only in patients
older than 18 years of age. Given its face validity and other
desirable properties, however, this scale could be used for
assessment of chronic GVHD in pediatric patients using
either child or parent report, after appropriate modiﬁcation
and psychometric evaluation [59]. Information may be ob-
tained by self-report from adolescents over 12 years of age.
For children who are 8 to 12 years of age, data should be
obtained with the assistance of parents and the health care
provider. Investigators are working on developing a symp-
tom scale appropriate for all pediatric patients [60].
The Lee Scale measures symptom bother as distinguished
from symptom intensity, which is reported on the forms in
Figure 2 [61]. The degree to which patients report that they
are bothered by a symptom represents a global assessment
incorporating not only the intensity of the symptom and its
frequency, but also the degree to which it causes emotional
disturbance or interferes with functioning. For example, oral
sensitivity may be severe, but patients may report that they
are not bothered or distressed by this symptom. By contrast,
skin itching may not be very intense or frequent but may
cause great distress. Additional study is needed to determine
the relationships between symptom intensity, frequency,
and distress or bother in patients with chronic GVHD and the
degree to which these are distinct dimensions of the symp-
tom experience.
Clinician-assessed and patient-reported global rating scales
Clinician perceptions. Physicians, nurse practitioners, or
physician assistants should provide a subjective assessment
of current overall chronic GVHD severity on a 4-point scale
(no chronic GVHD, mild, moderate, severe) [7] without
knowledge of the calculated NIH global severity score. They
should also provide an assessment of current overall chronic
GVHD severity on an 11-point numerical scale (0 indicates no
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GVHD symptoms possible) [62]. The categories of mild,
moderate, and severe have been used in previous studies for
patient and clinician assessment, where they were often
undeﬁned but showed good prognostic ability [7,63]. Clini-
cians should also provide their evaluations of chronic GVHD
changes since the last assessment scored on a 7-point scale
(verymuch better, moderately better, a little better, about the
same, a little worse, moderately worse, very much worse)
[9]. These semiquantitative assessments may detect quali-
tative improvements that are clinically meaningful but not
well captured using other measures [64]. The protocol and
case report form should specify the time interval for
assessing changes.
Patient perceptions. Similarly, at each assessment, patients
should score their perceptions of overall chronic GVHD
severity, overall severity of symptoms, and change in
symptom severity compared with the last assessment, using
the same response options used by clinicians.
The exact role of global scales in chronic GVHD response
assessments and their appropriate use as outcome measures
in clinical trials remain to be determined. These scales could
be sensitive to qualitative changes that might otherwise
escape detection if the assessments were limited to quanti-
tative measures. They are used in studies that establish
clinically meaningful differences in measures. A potential
limitation is that personality traits can inﬂuence patient
perceptions or self report [65].
Chronic GVHD Nonspeciﬁc Ancillary Measures
Nonspeciﬁc measures of function and patient-reported
outcomes related to functional status and health-related
quality of life could potentially offer additive objective and
subjective data regarding the effects of chronic GVHD and its
therapy. The GVHD nonspeciﬁc measures listed in Table 3
assess different dimensions of the patient experience.
These measures are strongly encouraged to allow investiga-
tion of the potential role of these nonspeciﬁc measures as
response measurements in chronic GVHD therapeutic clin-
ical trials.
Functional status
For an extremely complex, multisystem disease such as
chronic GVHD, objective measures of physical performance
and patient-reported measures of functional status could
represent important surrogate outcomes that might be more
informative than the measures described above for assessing
response in some situations (eg, advanced skin sclerosis). At
the very least, measures of functional status can provide
corroborative evidence of important changes after therapy. In
other patient populationswith chronic diseases [66-68], such
outcomes have been extensively applied, and population
norms for both physical performance measures and self-
reported functional status are available. Because the use of
functional endpoints in chronic GVHD assessment has not
been extensively tested, and as thesemeasures donot directly
assess chronic GVHD manifestations, functional status out-
comes can be used only as optional secondary endpoints in
chronic GVHD trials until further information is available.
An objective measure of physical performance is the 2-
minute walk distance (total distance in feet walked in 2
minutes) [69-71] measured at baseline as a prognostic factor
because it correlates with survival [72] but not as a response
measure at follow-up. Although measurement propertieshave been less thoroughly examined for the 2-minute walk
distance than those for the 6-minute walk distance in other
chronic diseases, the 2-minute walk distance could suffer
from a ceiling effect in patients without impaired physical
functioning. The 6-minute walk distance is often used as an
endpoint in nonehematopoietic cell transplantation lung
treatment trials [73]. Additional evaluation is needed to
determinewhether the 6-minute walk distance is superior in
unimpaired patients. Age-matched norms for 2-minute walk
distance are available for adults whereas age-matched norms
are available for the 6-minute walk test for children and
adolescents [74-76]. Of note, no data are currently available
to support the use of the 2-minute walk distance in pediatric
hematopoietic cell transplantation patients. Grip strength
[77-79] measured using a hydraulic dynamometer to capture
muscle strength of the upper extremity [80] is no longer
recommended, as it does not correlate with chronic GVHD
severity or outcome [72].
HAP. The strongly encouraged patient-reported measure of
physical activity in adults is the HAP questionnaire. The 94
questions are presented in ascending order according to the
metabolic equivalents of oxygen consumption required to
perform each activity [13]. The HAP, therefore, provides a
survey of activities that the patient performs independently
across a wide range of metabolic demand, beginning with
getting out of bed, bathing, dressing, performing a series of
progressively more physically demanding household chores,
and ending with running or jogging 3 miles in 30 minutes or
less. Although the HAP correlates with chronic GVHD
severity [72,81], it may not be necessary if the SF-36 is
collected, since the SF-36 also assesses physical activity. The
Working Group no longer recommends the Activities Scale
for Kids [82-84] because of lack of data in patients with
chronic GVHD.
Performance scales. The Karnofsky or Lansky Performance
Scale is commonly used in clinical assessments of chronic
GVHD and has prognostic value for survival, so it is strongly
encouraged at enrollment [85,86]. These scales are not valid
measures of response.
Health-Related quality of life
The effects of chronic GVHD and its treatment on general
physical and emotional health and health-related quality of
life are other endpoints that may be responsive to change as
a result of chronic GVHD therapy [87]. Because evidence of
sensitivity to change is lacking, these instruments are only
“strongly encouraged.” The SF-36 has had wide application
and is well accepted as a measure of self-reported general
health and the degree to which health impairments interfere
with activities of daily living and role function [11,88]. The
Functional Assessment of Chronic Illness Therapy is a suite of
health-related quality of life instruments that have well-
developed psychometric properties, have been used widely
in oncology, and have available population norms for those
with both mild and severe chronic illnesses, as well as for
cancer patients and survivors. The core measure (Functional
Assessment of Cancer Therapy-General [FACT-G]) is com-
bined with an additional 12-item disease-speciﬁc module
that evaluates concerns common to patients who have had
hematopoietic cell transplantation, and the entire instru-
ment is called the FACT-BMT [12]. The SF-36 (36 items) and
FACT-BMT (47 items) instruments are appropriate for adults;
however, they evaluate similar constructs and to minimize
Table 4
Response Determination for Chronic GVHD Clinical Trials based on Clinician Assessments
Organ Complete Response Partial Response Progression
Skin NIH Skin Score 0 after
previous involvement
Decrease in NIH Skin Score
by 1 or more points
Increase in NIH Skin Score by 1 or
more points, except 0 to 1
Eyes NIH Eye Score 0 after
previous involvement
Decrease in NIH Eye Score
by 1 or more points
Increase in NIH Eye Score by 1 or
more points, except 0 to 1
Mouth NIH Modiﬁed OMRS 0 after
previous involvement
Decrease in NIH Modiﬁed OMRS
of 2 or more points
Increase in NIH Modiﬁed OMRS
of 2 or more points
Esophagus NIH Esophagus Score 0 after
previous involvement
Decrease in NIH Esophagus
Score by 1 or more points
Increase in NIH Esophagus Score
by 1 or more points, except 0 to 1
Upper GI NIH Upper GI Score 0 after
previous involvement
Decrease in NIH Upper GI
Score by 1 or more points
Increase in NIH Upper GI Score
by 1 or more points, except 0 to 1
Lower GI NIH Lower GI Score 0 after
previous involvement
Decrease in NIH Lower GI
Score by 1 or more points
Increase in NIH Lower GI Score by 1
or more points, except from 0 to 1
Liver Normal ALT, alkaline
phosphatase, and Total
bilirubin after previous
elevation of 1 or more
Decrease by 50% Increase by 2  ULN
Lungs - Normal %FEV1 after
previous involvement
- If PFTs not available, NIH
Lung Symptom Score 0
after previous involvement
- Increase by 10% predicted
absolute value of %FEV1
- If PFTs not available, decrease
in NIH Lung Symptom Score
by 1 or more points
- Decrease by 10% predicted
absolute value of %FEV1
- If PFTs not available, increase in
NIH Lung Symptom Score by 1
or more points, except 0 to 1
Joints and fascia Both NIH Joint and Fascia
Score 0 and P-ROM score
25 after previous involvement
by at least 1 measure
Decrease in NIH Joint and Fascia
Score by 1 or more points or
increase in P-ROM score by 1
point for any site
Increase in NIH Joint and Fascia
Score by 1 or more points or
decrease in P-ROM score by 1
point for any site
Global Clinician overall severity score 0 Clinician overall severity score
decreases by 2 or more points
on a 0-10 scale
Clinician overall severity score
increases by 2 or more points
on a 0-10 scale
ULN indicates upper limit of normal.
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may be used alone. If the FACT-BMT is used, it should be
combined with the HAP to capture functional abilities. The
NIH Patient Reported Outcomes Measurement Information
System measures have not been studied in chronic GVHD,
but their evaluation is encouraged [89]. Previously
recommended pediatric scales, the Child Health Ratings In-
ventories (CHRIs) generic core and Disease-Speciﬁc Impair-
ment Inventory-Hematopoietic Stem Cell Transplantation
[90-92], are no longer recommended because of lack of
data in chronic GVHD. Instead, the Working Group recom-
mends exploration of the Pediatric Quality of Life based on
results in other chronic illnesses and hematopoietic cell
transplantation [93-95].
Cross-sectional studies have shown that chronic GVHD
has an adverse effect on quality of life [96], but the role of
quality of life as a measure of response to therapy or as a
predictor of long-term outcome remains to be deﬁned.
Patient-reported quality-of-life measures can augment, but
cannot replace, quantitative measures of chronic GVHD ac-
tivity in clinical trials. Because responses to patient surveys
may be affected by personality traits [65] and baseline status,
cross-sectional measurements may not be interpretable.CHRONIC GVHD DATA COLLECTION FORMS
Figures 1 and 2 provide downloadable data collection
forms for the recommended clinician-assessed and non-
copyrighted patient-reportedmeasures. It is not necessary to
include all recommended or strongly encouraged measures
in every trial, and judgment must be used in deciding which
items will best suit the needs of each study. Organ-speciﬁc
trials will likely add more detailed measures, perhaps
requiring subspecialist evaluations. In all studies, the mea-
sures to be collected and the timing of the assessments must
be speciﬁed.PROVISIONAL CRITERIA FOR DEFINITION OF RESPONSE
To assess response, disease manifestations at 2 pre-
deﬁned time points must be compared, and a judgment must
bemade as to whether themagnitude of any change qualiﬁes
as improvement or deterioration. This magnitude of change
should reﬂect genuine clinical change, and the criteria
should be clariﬁed and standardized as much as possible to
avoid measurement error. This standardization may be
relatively easy to establish for manifestations that can be
measured quantitatively with little day-to-day variation but
will be more difﬁcult to establish for manifestations that can
be measured only in more qualitative ways. The Working
Group proposes the following consensus deﬁnitions for
assessment of overall response and for measurable organ
response (Table 4).Objective Measures of GVHD Activity
Overall response
Three general categories of overall response are proposed
for interpretation of clinical trials: CR, PR, and lack of
response (unchanged, mixed response, progression). CR is
deﬁned as resolution of all manifestations in each organ or
site, and PR is deﬁned as improvement in at least 1 organ or
site without progression in any other organ or site as
described in the following sections on organ response. The
Working Group recommends that skin, mouth, liver, upper
and lower GI, esophagus, lung, eye, and joint/fascia be
considered in evaluating overall response. Genital tract and
othermanifestations are not included due to lack of validated
response measures.
Complete organ response
The term complete organ response indicates resolution of
all manifestations related to chronic GVHD in a speciﬁc or-
gan. This category may not apply to organs with irreversible
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a “near CR” category was justiﬁed to indicate resolution of all
reversible organ manifestations despite residual minor ab-
normalities. However, no consensus could be reached on the
deﬁnition of irreversibility, and there is no evidence yet that
the ultimate outcome after CR, near CR or PR differs. For
these reasons, no “near CR” category is included, and both CR
and PR are considered to be meaningful responses in clinical
trials.
Partial organ response
The proposed deﬁnition of PR in a speciﬁc organ requires
an improvement in score from baseline that reﬂects genuine
clinical beneﬁt and exceeds the measurement error of the
assessment tool: an improvement of 1 or more points on a 4
to 7epoint scale or an improvement of 2 or more points on a
10 to 12epoint scale. Partial response in the liver requires at
least a 50% improvement in alanine transaminase, alkaline
phosphatase, or total bilirubin. For patients with BOS, an
absolute improvement in %FEV1 of 10% predicted or more
(eg, 50% to 60%) is considered a PR [50] as long as the initial %
FEV1 is < 70%. Normalization (80%) is considered a CR.
Because the NIH 0 to 3 Skin Score is now recommended
for response assessment, even substantial improvement in
sclerotic features will not be considered responses unless the
NIH Skin Score improves. To aid in future measure devel-
opment and validation, recording the BSA involved with
nonmoveable sclerosis and collecting the severity of sclerosis
on a semiquantitative 0 to 10 scale is strongly encouraged.
Trials targeting sclerotic chronic GVHD should use more
detailed measures to document change in extent and func-
tional consequences of sclerosis.
Organ progression
Criteria for progression in each organ must be deﬁned, as
the overall category of partial response requires the absence
of progression in any organ. For skin, eye, esophagus, and
upper and lower GI tract, a worsening of 1 point or more on
the 0 to 3 scale is considered progression, except a change
from 0 to 1, which is considered trivial progression since it
often reﬂects mild, nonspeciﬁc, intermittent, self-limited
symptoms and signs that do not warrant a change of ther-
apy. One study showed poor test-retest reliability in 0 to 1 GI
changes, suggesting these minimal changes are also not
reliably measured [97]. For joint/fascia, a worsening of 1
point or more on the 0 to 3 scale is considered progression,
even if from 0 to 1, because a change to score 1 was
considered meaningful progression that would prompt a
change in therapy. For joints assessed by the photographic
range of motion, a worsening of 1 or more points for the 7-
point scales and 1 or more points for the 4-point scale is
considered progression. For mouth, a worsening of 2 or more
points on the 1-point scale indicates progression. Worsening
of liver GVHD is deﬁned by an increase of 2 or more times the
upper limit of normal for the assay for alanine transaminase,
alkaline phosphatase, or total bilirubin. For patients with
lung involvement, absolute worsening of FEV1 by 10% pre-
dicted or more (eg, 50% to 40%) is considered progression, as
long as the ﬁnal %FEV1 is < 65% (because initial %FEV1 must
be < 75% to establish the diagnosis of lung involvement). If
PFTs are not available, then worsening of the clinical lung
score based on symptoms by 1 or more points should be
scored as progression, except from score 0 to 1, which is
considered trivial progression because of its lack of speci-
ﬁcity for lung chronic GVHD. If the clinical lung symptomscore worsens from 0 to 1, PFTs are encouraged if lung
chronic GVHD is suspected.
For all organs, progression cannot be scored for mani-
festations with baseline values that are too close to the worst
score, especially the organs using 0 to 3 scales, raising the
possibility that patients could experience signiﬁcant clinical
worsening in an organ and still be considered a PR if they
have measurable improvement in another organ. However,
this concern is mitigated because many clinicians would
change therapy in such a situation, and any addition of a new
systemic immunosuppressive treatment is considered as
indicating a lack of response.
Mixed response
Mixed response is a newcategory deﬁned as CR or PR in at
least 1 organ accompanied by progression in another organ.
This category should be considered progression for the pur-
poses of analysis but may aid in identifying organ-speciﬁc
response patterns.
Unchanged
Outcomes that do not meet the criteria for CR, PR, DP or
mixed response are considered unchanged. These outcomes
will generally be considered nonresponders unless speciﬁed
otherwise by the protocol.
Limitations in measurement of organ responses
The response criteria do not account for qualitative
changes. Clinical experience indicates that clinically impor-
tant qualitative improvement often occurs before improve-
ment in the objective measures. For this reason, the response
criteria are not intended for use as the primary guide for
clinical decisions. Certain organs or rare manifestations are
not considered in the response criteria because quantitative
assessments are not feasible, but these may be the most
important manifestations of chronic GVHD for individual
patients. To capture qualitative and global changes of the
entire chronic GVHD syndrome, use of the clinician and pa-
tient assessed 0 to 10 global scale is strongly encouraged. The
response criteria also donot account for the prior trajectory of
abnormalities. For example, “stable” or “unchanged” disease
might be considered a meaningful response when the prior
trajectorywas clear progression, as indicated, for example, by
serial PFTs or rapidly progressive sclerosis, whereas “stable
disease” after prior improvement or stability should not be
considereda “response.” If theprior trajectory is important for
response determination, the protocol should specify data to
be documented in order to establish the trajectory.
Validation of response criteria
One study showed signiﬁcant prognostic value of the NIH
calculated responses for predicting survival in the context of
a therapeutic trial [47] but this conclusionwas not supported
by results from a large observational study [98]. The criteria
proposed in these guidelines have been modiﬁed based on
publications since 2005 but still need to be validated pro-
spectively for patients with chronic GVHD. For these reasons,
the updated criteria are still provisional and subject to
change with further clinical experience. Also, depending on
the stringency of response deﬁnitions required by the spe-
ciﬁc study, these general guidelines could be modiﬁed to ﬁt
the needs of a particular protocol. Because the criteria are
subject to change, we strongly recommend that case report
forms should always record the actual numerical values for
any measurement in order to allow future recategorization.
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Protocols must specify the times when response will be
assessed, generally 2 to 6 months after enrollment, and the
requirement(s) for durability of response. Permanent
discontinuation of systemic chronic GVHD therapy
conﬁrmed for the duration of the observation period in-
dicates a durable response. In principle, if additional systemic
therapy for chronic GVHD is added before the end of the
speciﬁed study period, the outcome is categorized as lack of
response. The protocol should specify whether dose changes,
for example increased steroid doses, are considered “addi-
tional systemic therapy.” Speciﬁc reasons for additional
systemic therapy should be collected, as new treatments are
sometimes added even though chronic GVHD is stable or
improving (eg, loss or change of insurance coverage, trans-
portation or logistical issues, loss of central i.v. access etc.),
and protocols should specify whether these cases should be
categorized as lack of response.
Occasionally patients have comorbid conditions that may
interfere with response assessment (for example, a viral
infection at the time of a planned PFT, temporary cholestasis
due to a gallstone) or pre-existing irreversible conditions (for
example, post-traumatic joint contracture, lung disease, etc).
In these situations, the abnormality should still be scored but
the check box (Figure 1) should also indicate that the ab-
normality is explained entirely by a non-GVHD documented
cause and the cause should be speciﬁed. Protocols should
specify whether response measures may be delayed to allow
resolution of a non-GVHD issue before response assessment
or whether an organ entirely explained by another non-
GVHD cause should be excluded for organ-speciﬁc or over-
all response assessment.
Addition of topical or organ-directed treatments gener-
ally make it impossible to be sure any response is due to
systemic immunosuppressive treatment. Thus, topical and
local therapy added after study enrollment must be docu-
mented in all patients and considered especially in patients
who have a complete or partial response. Sensitivity analyses
may be appropriate to determine whether exclusion of re-
sponses in the affected organs or sites changes the study
conclusions. Some topical or organ-directed therapies may
result in systemic effects due to absorption (eg, oral, GI tract,
lung, skin) or effects beyond the target organ (eg, mon-
telukast), and protocols should specify whether such treat-
ments are allowed during the course of the trial or would
automatically indicate a lack of response.
Patient-Reported Measures of GVHD Activity
Although improvement in patient functioning and
symptoms is recognized as a measure of clinical beneﬁt, the
Working Group recommends that such outcomes be
tabulated separately from clinician-assessed responses. The
terms CR, PR, and DP do not technically apply to patient-
reported or functional measures data. Patient-reported
outcomes should be classiﬁed into response (clinically
meaningful improvement) versus no response (no
improvement or worsening), as measured by change
between baseline and follow-up scores. The deﬁnition of
improvement or worsening for such scales is based on the
reliability of the measure (the variability due to measure-
ment error) and is anchored against clinically perceptible
changes. For global ratings and categorical scales, a 1-point
change on a 0 to 3 or 1 to 7epoint scale, or a 2-point
change (.5 standard deviation change) on a 0 to 10epoint
scale could be considered clinically meaningful.Unless otherwise speciﬁed, for all patient-reported mea-
sures, a change of .5 standard deviation may be considered
clinically meaningful for normally distributed data [99,100].
For example, a distribution-based analysis was used to deﬁne
improvement as a change of 6 to 7 points (.5 SD) on the total
chronic GVHD symptom score [7]. For the physical and
mental component summary scores for the SF-36, a change
of 5 points is considered clinically meaningful [101,102]. For
HAP, clinically meaningful improvement is deﬁned as a 10-
point increase in the maximum activity score, as a change
of this magnitude is sufﬁcient to change the disability cate-
gory at the middle of the scale.
An area for future investigation is to determine methods
to integrate objective and subjective measures into holistic
assessments of chronic GVHD disease activity. This approach
has been used successfully in other autoimmune diseases.
Examples include the American College of Rheumatology
criteria for rheumatoid arthritis [103,104], Crohn’s Disease
Activity Index [105,106] Ankylosing Spondylitis Short-Term
Improvement Criteria [107], the Systemic Lupus Erythema-
tosus Disease Activity Index 2000 [108-111], Systemic Lupus
Erythematosus Responder Index [112], and the British Isles
Lupus Assessment Group [113,114].
USE OF RESPONSE ASSESSMENT AS A PRIMARY
ENDPOINT IN CLINICAL TRIALS
Use of the recommended measures and methods of
calculating response has at least 2 important advantages.
First, the ﬁeld will gain valuable experience with the mea-
sures to help validate them in the context of therapeutic
clinical trials. Second, the use of standardized assessment
methods will allow comparison of efﬁcacy between agents.
At the same time, it will be possible to recalculate response
categories if new information becomes available. Valid
methods are urgently needed to document whether chronic
GVHD is responding adequately.
More sophisticated assessments of certain organs, such as
skin, eyes, mouth, female genital tract, and joints may be
needed for certain studies [14-19,21,22,25,26,115]. Special-
ized expertise will be needed for these assessments, and
efforts to deﬁne the criteria for measurement of response in
these situations exceed the scope of the current proposal.
The Working Group encourages development and validation
ofmore precise assessment tools that could be used in organ-
speciﬁc trials. In situations where expert assessors are not
readily available, objective assessments of the skin, mouth,
eye and external genitalia might be enhanced through re-
view of serial photographs by a panel of expert individuals as
blinded assessors who have no other information about the
patient, so as to avoid bias andminimize potential inter-rater
differences [33].
Note that this document addresses only themeasurement
of clinical responses. It does not address other suggested
surrogate endpoints, such as failure-free survival, deﬁned as
absence of relapse, death and addition of new treatment
[116,117], survival free of impairment, or reduction in steroid
dosing that do not rely on direct assessment of organ
responses.
FUTURE DIRECTIONS
The proposed response criteria are expected to enhance
uniformity and feasibility of data collection methods and
further advance standards of chronic GVHD clinical trials.
Although this 2014 proposal is based on substantial interim
evidence of utility and suggested clinical beneﬁt for many
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tested further in prospective chronic GVHD therapy trials.
Algorithms for measuring combinations of organ-speciﬁc
and global responses to assess overall therapy response,
and deﬁnition of minimal clinically meaningful cut-off points
may help in the development of highly relevant chronic
GVHD response measurement tools, as demonstrated for
other systemic inﬂammatory diseases. Improved methods
will be needed to distinguish chronic GVHD disease activity
from irreversible damage, leading toward development of a
chronic GVHD activity index for clinical trials. The develop-
ment and validation of laboratory biomarkers that reﬂect
chronic GVHD activity could enhance methods based on
clinical assessment.
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